A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancerPRRX2 drives enzalutamide resistance in prostate cancer

Overview of attention for article published in Cancer Research, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 2 news outlets

twitter: 12 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 13 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Researchers discover new gene that confers resistance to prostate cancer treatment

The Medical News, 13 May 2022

Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment…

Researchers discover new gene that confers resistance to prostate cancer treatment

Opera News, 13 May 2022

Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.